Industry and Geographic Information

3 Months Ended

Mar. 31, 2018

Industry And Geographic Information [Abstract]

The Company operates in one reportable segment. Sales to customers outside the U.S. represented $41.9 million (25%) and $8.3 million (11%) of total revenue for the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018 and December 31, 2017, balances due from foreign customers were $22.0 million and $18.8 million, respectively.

The Company had sales to individual customers in excess of 10% of total revenues, as follows:



	Three months ended March 31,
	2018		2017
Customer:
A	20	%	17	%
B	16	%	27	%
C	13	%	15	%
	49	%	59	%

Consolidated net revenues by product category for the three months ended March 31, 2018 and 2017 are as follows (in thousands):



	Three months ended March 31,
	2018		2017
Rapid Immunoassay	$	80,685	$	57,533
Cardiac Immunoassay	68,444		—
Specialized Diagnostic Solutions	14,871		13,048
Molecular Diagnostic Solutions	5,143		3,111
Total revenues	$	169,143	$	73,692

As of March 31, 2018 and December 31, 2017, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $58.4 million and $44.4 million, respectively.